Virtual Reality for Pain in Acute Orthopedic Injuries

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05552430
Collaborator
(none)
10
1
9.5

Study Details

Study Description

Brief Summary

The goal of this study is to pilot test a skills-based virtual reality (VR) for acute orthopedic injury. It will measure the feasibility, signals of improvement, exploratory pain mechanisms, and user experience of an established skills-based program (RelieveVRx) for acute orthopedic injury.

Condition or Disease Intervention/Treatment Phase
  • Device: RelieveVRx
N/A

Detailed Description

This study will use mixed-methods to investigate the feasibility of skills-based virtual reality (VR) for acute orthopedic injury in an open pilot with individual exit interviews (target N=10). Participants will be patients with acute orthopedic musculoskeletal injuries who are at risk for chronic pain and disability (PCS ≥ 20 and PASS-20 ≥ 40) and meet inclusionary/exclusionary criteria. Participants will be recruited through the MGH Orthopedics Department, flyers, and the Rally research platform. Participants will self-administer a skills-based virtual reality (VR) program at home over an 8-week period. The primary outcome for the pilot will be a-priori Go/No-Go feasibility markers (feasibility, acceptability, fidelity, credibility, expectancy, satisfaction) of the VR program and data collection procedures to increase the success of subsequent trials. Exploratory measures include: multi-modal assessment of pain intensity, pain-specific coping (catastrophizing, self-efficacy, acceptance), disability, physical function, and emotional function (depression, anxiety, stress). The VR headset will collect usage data and daily smartphone surveys will track changes in pain during the 8-week intervention. Completers will have the opportunity to attend 30 min individual exit interviews to understand patients' perception of the VR and their experience with the study procedures to increase the success of larger trials.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Physical and Psychological Measures of Pain in Acute Orthopedic Injuries: Use of At-home Virtual Reality
Anticipated Study Start Date :
Oct 17, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Skills-Based VR

Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.

Device: RelieveVRx
Participants will complete daily skills-based Virtual Reality (VR) sessions for 8 weeks (an average of 6 minutes per day) to determine the feasibility of at-home VR technology to aid the recovery of acute orthopedic musculoskeletal injuries. The VR device software is equipped with pain-specific treatment modules (e.g., Pain Education, Relaxation/Interoception, Mindful Escapes, and Pain Distraction Games) derived from evidence-based principles of cognitive behavioral therapy (CBT), mindfulness, and pain neuroscience education.

Outcome Measures

Primary Outcome Measures

  1. Credibility and Expectancy Questionnaire [Pre-intervention (week 0) only]

    Participants' treatment expectancy and perceived credibility, determined by the percentage of participants with scores (range = 3-27) over the scale's midpoint (≥70% good, ≥ 80% excellent).

  2. Client Satisfaction Questionnaire [Post-intervention (week 8) only]

    Participants' treatment satisfaction, determined by the percentage of participants with scores (range = 3-12) over the scale's midpoint (≥70% good, ≥ 80% excellent).

  3. System Usability Scale [Post-intervention (week 8) only]

    Assess global user experience of the VR device, with higher percentile rankings (range = 0-100) indicating greater usability.

Secondary Outcome Measures

  1. Patient's Global Impression of Change [Post-intervention (week 8) only]

    Assess perceptions of overall improvement in pain and physical function during the program.

  2. Motion Sickness and Nausea [Post-intervention (week 8) only]

    Assess adverse experiences with VR, determined by the percentage of participants with responses (range = 0 never to 3 always) below the scale's midpoint (≥70% good, ≥ 80% excellent).

  3. Feasibility of Recruitment [Throughout the study completion, approximately 1 year]

    We will report number of participants who agree to participate out of those approached, evaluated at the end of study for all participants (≥70% good, ≥ 80% excellent).

  4. Acceptability of Treatment [Pre-intervention (week 0), Post-intervention (week 8)]

    Acceptability of virtual reality based on module completion (≥70% complete 6 out of 8 weeks, good; ≥ 80% complete 6 out of 8 weeks, excellent).

  5. Adherence to Pain Surveys [Pre-intervention (week 0), Post-intervention (week 8)]

    Adherence to smartphone-based surveys of pain intensity (at rest, with activity) and pain interference with daily activities in the last 24 hours (≥70% good, ≥80% excellent).

  6. Feasibility of Outcome Assessments [Pre-intervention (week 0), Post-intervention (week 8)]

    Feasibility of collecting complete outcome assessments (≥70% have no missing data, good; ≥80% have no missing data, excellent).

Other Outcome Measures

  1. Pain medications [Pre-intervention (week 0), Post-intervention (week 8)]

    Number of days that narcotic and non-narcotic pain medications were taken in the last week.

  2. Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess one's ability to carry out activities that require physical actions, ranging from self-care to social and work.

  3. Short Musculoskeletal Functional Assessment (SMFA) Questionnaire [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess disability specific to musculoskeletal injury and pain.

  4. Numerical Rating Scale (NRS) [Pre-intervention (week 0), Bi-weekly, Post-intervention (week 8)]

    Assess pain intensity at rest and with activity.

  5. Pain Catastrophizing Scale (PCS) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess catastrophic thinking about pain.

  6. Pain Anxiety Scale (PASS) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess pain-specific anxiety.

  7. Pain Self-Efficacy Questionnaire (PSEQ) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess confidence to engage in physical activity despite pain.

  8. Chronic Pain Acceptance Questionnaire (CPAQ) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess ability to engage in meaningful activities despite pain.

  9. Center for Epidemiologic Study of Depression (CESD) Scale [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess depression.

  10. Cognitive and Affective Mindfulness Scale (CAMS) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess state of mindfulness taught during the program.

  11. Defense and Veterans Pain Rating Scale (DVPRS) [Pre-intervention (week 0), Bi-weekly, Post-intervention (week 8)]

    Assess pain interference and pain intensity

  12. Measure of Current Status (MOCS) [Pre-intervention (week 0), Post-intervention (week 8)]

    Assess general coping ability taught during the program.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Outpatient adults in the Level 1 Trauma Center

  2. Age 18 or older

  3. Able to meaningfully participate meaningfully (English fluency and literacy) and stable living situation

  4. Acute musculoskeletal injury (e.g., fracture, dislocation, rupture) 1-2 months earlier (acute phase).

  5. Pain Catastrophizing Scale ≥20 or Pain Anxiety Symptom Scale-20 ≥40

  6. Has access to internet (Wi-Fi or wireless)

  7. Willing to participate and comply with the requirements of the study protocol, including virtual reality program and questionnaire completion No psychotropics or stable for >6 weeks

  8. Free of concurrent psychotropic medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic medication for a minimum of 6 weeks and willing to maintain a stable dose (i.e., no psychotropics or stable for >6 weeks)

  9. Cleared by orthopedic surgeon for study participation

Exclusion Criteria:
  1. Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines, or other neurological diseases that are contraindicated for VR

  2. Medical condition predisposing to nausea or dizziness.

  3. Hypersensitivity to flashing light or motion.

  4. Vision or severe hearing impairment.

  5. Injury to eyes, face, or neck that impedes comfortable use of virtual reality

  6. Diagnosed with a medical illness expected to worsen in the next 3 months (e.g., malignancy)

  7. Other serious injuries that occurred with the orthopedic injury or surgical complications (e.g., infection, need for repeat surgery)

  8. Current or prior untreated mental illness, substance use disorder, or suicidal ideation

  9. Self-reported pregnancy

  10. Currently in litigation or under Workman's Comp

  11. Practice of cognitive-behavioral therapy, yoga/meditation, or other mind body techniques once per week for 45 minutes or more within the last 3 months

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Ryan A Mace, PhD, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ryan A., Mace, PHD, Staff Psychologist, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05552430
Other Study ID Numbers:
  • 2022P001500
First Posted:
Sep 23, 2022
Last Update Posted:
Sep 26, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Ryan A., Mace, PHD, Staff Psychologist, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 26, 2022